^
Association details:
Biomarker:KDR amplification
Cancer:Sarcoma
Drug:pazopanib (Multi-tyrosine kinase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Source:
Title:

Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib

Excerpt:
This report presents a patient with a sporadic, cutaneous angiosarcoma harboring high-level amplifications of members of the VEGFR family, specifically VEGFR2 (KDR; 8x) and VEGFR3 (FLT4; 16x). In response to pazopanib, an inhibitor of both VEGFR2 and VEGFR3, the patient experienced disease control for 6 month.
DOI:
10.6004/jnccn.2016.0058